Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 4, 2017

Abiomed begins enrolment for STEMI DTU study of Impella CP in MI

US-based medical devices developer Abiomed has started patient enrolment in the ST segment elevation myocardial infarction (STEMI) door to unloading (DTU) clinical study of its Impella CP system to treat acute myocardial infarction (MI).

US-based medical devices developer Abiomed has started patient enrolment in the ST segment elevation myocardial infarction (STEMI) door to unloading (DTU) clinical study of its Impella CP system to treat acute myocardial infarction (MI).

Impella CP is a heart pump designed to pull blood from the left ventricle via an inlet area located near the tip while delivering it into the ascending aorta through the catheter.

The device can be inserted through the femoral artery, into the ascending aorta, across the valve and into the left ventricle using a traditional catheterisation procedure.

The prospective, multi-center study will enrol approximately 50 patients at ten sites.

It will evaluate the safety and feasibility of using the Impella CP to unload the left ventricle before primary percutaneous coronary intervention (PCI) in patients with STEMI and without cardiogenic shock.

"The trial is being conducted on the assumption that the device will decrease the infarct size, myocardial workload and oxygen demand while initiating a cardio-protective effect."

Estimated to be completed within 18 months, the trial is being conducted on the assumption that the device will decrease the infarct size, myocardial workload and oxygen demand while initiating a cardio-protective effect.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The study's primary endpoints are safety and the adverse cardiovascular and cerebrovascular events (MACCE).

The infarct size as a percentage of left ventricular mass will be examined through cardiac magnetic resonance (CMR) imaging after 30 days of PCI.

Patients will receive Impella CP placement with immediate primary PCI or 30 minutes of unloading prior to primary PCI.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU